Moreover, for the first time, AREG was identified to promote in vivo tumor metastasis and reverse miR-34a-imposed metastasis defects, indicating that AREG is the key determinant in the maintenance of metastatic properties of HNSCC, and a potential therapeutic target for metastatic tumor. Here, AREG is linked to head and neck squamous cell carcinoma.